Evidence map›Paper›PMID 29399531›Full record

ReviewCardiovascular diagnosis and therapy2017

Deep vein thrombosis: pathogenesis, diagnosis, and medical management.

Jonathan Stone, Patrick Hangge, Hassan Albadawi, Alex Wallace, Fadi Shamoun, M Grace Knuttien, Sailendra Naidu, Rahmi Oklu

Open access · hybridAbstract readReview
In one paragraph

Review in Cardiovascular diagnosis and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 8 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 8 syntheses or guidelines pooled it, 358 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Calf Muscle Vein Thrombosis After Hip and Lower-Limb Fracture Surgery: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jonathan StoneDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Patrick HanggeDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Hassan AlbadawiDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Alex WallaceDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Fadi ShamounDivision of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, USA.
M Grace KnuttienDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Sailendra NaiduDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Rahmi OkluDivision of Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
WinnMed · USMayo Clinic in Florida · US

Funding

Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Targeted chemotherapy delivery and captureR01EB024403 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2017 to 2020
$2.2M
Catheter guided endovascular electric field ablation for thrombosis therapy.R21EB021148 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2016 to 2017
$485k
Circulating tumor cells in hepatocellular carcinomaR03CA172738 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2013 to 2014
$171k
NCI NIH HHS R03 CA172738NHLBI NIH HHS R01 HL137193NIBIB NIH HHS R01 EB024403NIBIB NIH HHS R21 EB021148
6 · The paper itself

Abstract

Deep vein thrombosis (DVT) is a major preventable cause of morbidity and mortality worldwide. Venous thromboembolism (VTE), which includes DVT and pulmonary embolism (PE), affects an estimated 1 per 1,000 people and contributes to 60,000-100,000 deaths annually. Normal blood physiology hinges on a delicate balance between pro- and anti-coagulant factors. Virchow's Triad distills the multitude of risk factors for DVT into three basic elements favoring thrombus formation: venous stasis, vascular injury, and hypercoagulability. Clinical, biochemical, and radiological tests are used to increase the sensitivity and specificity for diagnosing DVT. Anticoagulation therapy is essential for the treatment of DVT. With few exceptions, the standard therapy for DVT has been vitamin K-antagonists (VKAs) such as warfarin with heparin or fractionated heparin bridging. More recently, a number of large-scale clinical trials have validated the use of direct oral anticoagulants (DOACs) in place of warfarin in select cases. In this review, we summarize the pathogenesis, diagnosis, and medical management of DVT, with particular emphasis on anticoagulation therapy and the role of DOACs in the current treatment algorithm.

Indexed as

anticoagulantsDeep vein thrombosis (DVT)direct oral anticoagulants (DOACs)vitamin K-antagonists (VKAs)warfarin

Identifiers

PMID29399531
PMCPMC5778510
OpenAlexW2762298725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.